The Supreme Court returned its verdict in the Myriad gene patenting case, declaring in a 9-0 decision that isolated DNA is not patentable, but that complementary DNA (cDNA) is, a verdict that left Myriad Genetics (Salt Lake City, Utah) with a bump on Wall Street. The decision closes months of intense anticipation on the parts of the diagnostics and biotechnology industries, which were trying to anticipate how the outcome might affect their futures. Myriad's share prices at Nasdaq rose almost 10% upon the announcement, making clear that investors are happy with the outcome.